Ana García Tapiador

Oncologa Médica. Cancer de mama y ginecológico.

[GEICAM - Cáncer de mama @GEICAM]

🔬🟣 @GEICAM is already at #ASCO2026, where these days have already been filled with many valuable and inspiring meetings, and day one has kicked off with two oral presentations from international collaborative research featuring authors from our group 👇

🔹NATALEE trial
This new analysis from the #NATALEE trial evaluated the prognostic and predictive value of baseline gene expression in stage II/III HR+/HER2- early #breastcancer treated with adjuvant ribociclib plus a nonsteroidal aromatase inhibitor versus aromatase inhibitor alone 🧬 Following the previously reported invasive disease-free survival benefit with #ribociclib, this subanalysis included more than 3,000 tumor samples assessed with the NanoString BC360 panel, including #PAM50 molecular subtyping 💊 Ribociclib showed consistent benefit across all molecular subtypes, while greater benefit was observed in patients with higher genomic risk or proliferation, suggesting a potential role for gene expression profiling in future patient selection.

🔹lidERA BC clinical trial
This phase III study compared #giredestrantwith standard endocrine therapy in pre- and postmenopausal women with stage I–III ER+/HER2- early breast #cancer previously treated with surgery and #chemotherapy when indicated 🧫 In 4,170 patients, giredestrant improved invasive disease-free survival across both menopausal groups and reduced the risk of #metastatic disease 📊 It also showed a comparable safety profile with fewer treatment discontinuations due to toxicity, particularly musculoskeletal pain, supporting its potential as an effective and better-tolerated alternative.

🙌 We are especially proud of the entire team who travelled to Boston, and particularly of Dr. Miguel Martín, founder of GEICAM and its President for 30 years until last year, whose contribution as an author to both studies reflects the long-standing commitment and dedication of our investigators to advancing #GEICAM #BreastCancerResearch #ASCO26. 🙌🚀

@ASCO @ASCOPost @oncofir

[Dr Rishabh Jain @DrRishabhOnco]

#ASCO26

ER+, HER2- breast cancer management is becoming less about “one-size-fits-all” and more about precision escalation vs precision de-escalation.

The future is clear:
🧬 Biomarkers decide who gets chemo
💊 CDK4/6 inhibitors move earlier
🩺 Endocrine therapy intensifies in high-risk disease
⚖️ Obesity and supportive care become survival interventions

Key themes from ASCO 2026:
▪️ Anthracyclines may still matter in selected genomically high-risk patients
▪️ Some node+ patients may safely avoid chemotherapy
▪️ OFS + AI remains critical for high-risk premenopausal disease
▪️ Adjuvant abemaciclib and ribociclib continue reshaping standards
▪️ Oral SERDs are entering early breast cancer
▪️ Weight management may become part of oncologic care itself

Breast oncology is shifting from anatomy-driven to biology-driven treatment selection.

Which biomarker do you think will have the biggest impact in early ER+ breast cancer over the next 5 years? 👀

@OncoAlert @ASCO @myesmo @esmo_open @larvol

#OncoTwitter #MedTwitter #BreastCancer #bcsm #PrecisionOncology

[Paolo Tarantino @PTarantinoMD]

Tremendous discussion by @drsarahsam, highlighting the promise of several escalation/substitution strategies across breast cancer subtypes, but reminding the costs and caveat of each new option. #ASCO26

[AstraZeneca España @AstraZenecaES]

La atención en el cáncer de mama metastástásico va más allá del tratamiento. La confianza y la comunicación con el equipo sanitario es muy importante para acompañar a las pacientes. Desde la Alianza @DaiichiSankyoES | AstraZeneca y la
@CMMetastasico trabajamos por un abordaje integral de la patología.

[Paolo Tarantino @PTarantinoMD]

@ErikaHamilton9 presents primary results from HER2CLIMB-05: adding tucatinib to 1L maintenance HP significantly improved PFS; most benefit in ER-/HER2+ disease (delta 12 mo). More diarrhea and liver tox with tucatinib. New SoC maintenance option after induction for ER-/HER2+ MBC!

[Annals of Oncology @Annals_Oncology]

🆕article in press: Kinetics and determinants of ESR1 mutation detection in metastatic breast cancer. @BarbaraPistill2 Read it here: https://t.co/QfuFBGXbMF

[Dana-Farber’s Breast Oncology Center @DFCI_BreastOnc]

Results of DESTINY-Breast09 are now available in @NEJM! 👉#TrastuzumabDeruxtecan plus #Pertuzumab for HER2-Positive #MetastaticBreastCancer.
🔓https://t.co/E9J7UiZzKU
@stolaney1 @ToiMasakazu #BreastCancere #MBC

[Ana García Tapiador @Latapiador]

https://t.co/In1RHcwlaz

[Ana García Tapiador @Latapiador]

#diamundialcancerdemama

[Daiichi Sankyo España @DaiichiSankyoES]

Desde la Alianza Daiichi Sankyo | @AstraZenecaES y la @CMMetastasico continuamos con los Diálogos #laMquefalta, una iniciativa de sensibilización sobre el abordaje integral del #CáncerDeMamaMetastásico.

Os mostramos el segundo encuentro en el Hospital Universitario de Toledo 👇

[Ana García Tapiador @Latapiador]

Día del cáncer de mama #vaporellas https://t.co/kfojpBEAXB

[Ana García Tapiador @Latapiador]

Hago un llamamiento a la responsabilidad de @Renfe @Adif_es por los continuos retrasos en el trayecto en tren Madrid-Toledo. No somos turistas, somos trabajadores que llegamos tarde a trabajar a diario. Ajusten los horarios para que cumplamos con nuestro horario laboral

[Sara Tolaney @stolaney1]

RxPONDER: AMH (low levels associated w/ diminished ovarian reserve) in women classified as premenopausal

If low AMH --> no benefit from adj chemo
If med/high AMH--> ⬆️4.4% in 5 yr DRFS w/ chemo

Suggests:chemo impact may be due to impact on ovarian fxn

@OncoAlert #ASCO24

[GEICO-Spanish Gynaecological Cancer Research Group @GEICOgroup]

Muchos de nuestros miembros están estos días en #ASCO24... ¡Estamos impacientes de que nos cuenten todo lo que se está presentando en el congreso sobre #tumoresginecológicos! #teamGEICO

[Paolo Tarantino @PTarantinoMD]

When you have a full #ASCO24 room at 7 am, you know it will be a pretty relevant session. #DB06 @curijoey

[Matteo Lambertini, MD PhD @matteolambe]

Great discussion by dr Krop @Yale: here the new algorithm for the management of hormone receptor-positive/HER2-negative advanced #BreastCancer after #ASCO24
@OncoAlert

[Ainhoa Madariaga @AinhoaMada]

Outstanding presentation by @StephanieLheur5 of the #NEO randomized phase II trial assessing the role of neoadjuvant olaparib in PlatS ovarian cancer
#ASCO24 @pmcancercentre

[Ana García Tapiador @Latapiador]

@analauraortega Peor que DiCaprio en el Titanic

[MamaCentro @MamaCentro]

Primera ponencia del día. Gorka Benítez: Objetivos realistas en cuanto a ejercicio y cáncer de mama. "Hay que ir progresando poco a poco, con individualización. NECESIDAD clara del sistema sanitario".

#IISimposioMamaCentro

#EjercicioFisicoyCancer